Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2013

01-08-2013 | Clinical trial

Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer

Authors: Luigi Di Lauro, Patrizia Vici, Pietro Del Medico, Lucio Laudadio, Silverio Tomao, Diana Giannarelli, Laura Pizzuti, Domenico Sergi, Maddalena Barba, Marcello Maugeri-Saccà

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Login to get access

Abstract

The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown. In this retrospective study we evaluated the activity of letrozole combined with a gonadotropin-releasing hormone analog as a first- or second-line therapy for metastatic male breast cancer patients. 19 men entered the study. We did not observe any grade 3 or 4 adverse events. 2 patients (10.5 %) had complete response, 7 patients (36.8 %) experienced a partial response, 7 patients (36.8 %) had stable disease lasting ≥6 months, and 3 patients (15.8 %) had progressive disease. Overall, the disease control rate was 84.2 %. Median progression-free survival was 12.5 months (95 % CI 8.2–16.9), median overall survival was 35.8 months (95 % CI 24.4–49.2), 1- and 2-year survival rates were 89.5 and 67 %, respectively. Interestingly, 3 out of 4 patients treated with the combination following disease progression while on aromatase inhibitor monotherapy confirmed or improved the best overall response observed in the first-line setting. The combination of letrozole and gonadotropin-releasing hormone analog is effective and safe in hormone-receptor positive, metastatic male breast cancer patients.
Literature
1.
go back to reference Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24:1434–1443 Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24:1434–1443
3.
go back to reference Johansson I, Nilsson C, Berglund P et al (2012) Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies nacetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 14:R31PubMedCentralPubMedCrossRef Johansson I, Nilsson C, Berglund P et al (2012) Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies nacetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 14:R31PubMedCentralPubMedCrossRef
4.
go back to reference Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28:232–239PubMedCentralPubMedCrossRef Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 28:232–239PubMedCentralPubMedCrossRef
5.
go back to reference Cardoso F, Bischoff J, Brain E et al (2013) A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 39:457–465PubMedCrossRef Cardoso F, Bischoff J, Brain E et al (2013) A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women. Cancer Treat Rev 39:457–465PubMedCrossRef
6.
go back to reference Eggemann H, Ignatov A, Smith BJ et al (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465–470PubMedCrossRef Eggemann H, Ignatov A, Smith BJ et al (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465–470PubMedCrossRef
7.
go back to reference Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I (2002) Estradiol in elderly men. Aging Male 5:98–102PubMedCrossRef Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I (2002) Estradiol in elderly men. Aging Male 5:98–102PubMedCrossRef
8.
go back to reference Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC (1974) Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38:476–479PubMedCrossRef Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC (1974) Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38:476–479PubMedCrossRef
9.
go back to reference Mauras N, O’Brien KO, Klein KO, Hayes V (2000) Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85:2370–2377PubMed Mauras N, O’Brien KO, Klein KO, Hayes V (2000) Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85:2370–2377PubMed
10.
go back to reference T’Sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman JM (2005) Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab 90:5717–5722PubMedCrossRef T’Sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman JM (2005) Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition. J Clin Endocrinol Metab 90:5717–5722PubMedCrossRef
11.
go back to reference Callari M, Cappelletti V, De Cecco L et al (2011) Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 127:601–610PubMedCrossRef Callari M, Cappelletti V, De Cecco L et al (2011) Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat 127:601–610PubMedCrossRef
12.
13.
go back to reference Lopez M, Di Lauro L, Lazzaro B, Papaldo P (1985) Hormonal treatment of disseminated male breast cancer. Oncology 42:345–349PubMedCrossRef Lopez M, Di Lauro L, Lazzaro B, Papaldo P (1985) Hormonal treatment of disseminated male breast cancer. Oncology 42:345–349PubMedCrossRef
14.
go back to reference Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S (1993) Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer 72:502–505PubMedCrossRef Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S (1993) Combined treatment with buserelin and cyproterone acetate in metastatic male breast cancer. Cancer 72:502–505PubMedCrossRef
15.
go back to reference Doberauer C, Niederle N, Schmidt CG (1988) Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 62:474–478PubMedCrossRef Doberauer C, Niederle N, Schmidt CG (1988) Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 62:474–478PubMedCrossRef
16.
go back to reference Patterson JS, Battersby LA, Bach BK (1980) Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 64:801–804PubMed Patterson JS, Battersby LA, Bach BK (1980) Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 64:801–804PubMed
17.
go back to reference Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D (2007) Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 105:169–175PubMedCrossRef Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D (2007) Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 105:169–175PubMedCrossRef
18.
go back to reference Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A (2010) Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 21:1243–1245PubMedCrossRef Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A (2010) Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 21:1243–1245PubMedCrossRef
19.
go back to reference Turner KJ, Morley M, Atanassova N, Swanston ID, Sharpe RM (2000) Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 164:225–238PubMedCrossRef Turner KJ, Morley M, Atanassova N, Swanston ID, Sharpe RM (2000) Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 164:225–238PubMedCrossRef
20.
go back to reference Giordano SH, Hortobagyi GN (2006) Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24:e42–e43PubMedCrossRef Giordano SH, Hortobagyi GN (2006) Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24:e42–e43PubMedCrossRef
21.
go back to reference Zagouri F, Sergentanis TN, Koutoulidis V et al (2013) Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108:2259–2263PubMedCentralPubMedCrossRef Zagouri F, Sergentanis TN, Koutoulidis V et al (2013) Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108:2259–2263PubMedCentralPubMedCrossRef
22.
go back to reference Giordano SH, Valero V, Buzdar AU, Hortobagyi GN (2002) Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25:235–237PubMedCrossRef Giordano SH, Valero V, Buzdar AU, Hortobagyi GN (2002) Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25:235–237PubMedCrossRef
23.
go back to reference Italiano A, Largillier R, Marcy PY et al (2004) Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne 25:323–324PubMedCrossRef Italiano A, Largillier R, Marcy PY et al (2004) Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne 25:323–324PubMedCrossRef
24.
go back to reference Zabolotny BP, Zalai CV, Meterissian SH (2005) Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90:26–30PubMedCrossRef Zabolotny BP, Zalai CV, Meterissian SH (2005) Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90:26–30PubMedCrossRef
25.
go back to reference Arriola E, Hui E, Dowsett M, Smith IE (2007) Aromatase inhibitors and male breast cancer. Clin Transl Oncol 9:192–194PubMedCrossRef Arriola E, Hui E, Dowsett M, Smith IE (2007) Aromatase inhibitors and male breast cancer. Clin Transl Oncol 9:192–194PubMedCrossRef
Metadata
Title
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer
Authors
Luigi Di Lauro
Patrizia Vici
Pietro Del Medico
Lucio Laudadio
Silverio Tomao
Diana Giannarelli
Laura Pizzuti
Domenico Sergi
Maddalena Barba
Marcello Maugeri-Saccà
Publication date
01-08-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2675-y

Other articles of this Issue 1/2013

Breast Cancer Research and Treatment 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine